To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Platelet-Rich Plasma vs. Corticosteroid Injection for Partial Supraspinatus Tears

Download
Share
Reprints
Cite This
About
+ Favorites
Download
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
October 2021

Platelet-Rich Plasma vs. Corticosteroid Injection for Partial Supraspinatus Tears

Vol: 104| Issue: 1| Number:2| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Comparison of a Platelet-Rich Plasma Injection and a Conventional Steroid Injection for Pain Relief and Functional Improvement of Partial Supraspinatus Tears.

Orthop J Sports Med . 2021 Sep 1;9(9):23259671211024937.

Contributing Authors:
M Thepsoparn P Thanphraisan T Tanpowpong T Itthipanichpong

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Thirty two patients with partial supraspinatus tears were randomized to receive a platelet-rich plasma (PRP) intratendinous injection (n=16) or a subacromial corticosteroid injection (n=16). The outcomes of interest were pain as measured by the Visual Analogue Scale (VAS) and function measured by the Oxford Shoulder Score (OSS). There was no significant differences in VAS or OSS scores between the...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue